You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Humanized Monoclonal Antibodies to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Immunotherapeutics to prevent HCV reinfection

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru

    SBC: DFH Pharma, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite advances in the development of HIV drugs there remains a need for new therapies. Toxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antivirals. Maturation inhibitors (MIs) represent one such class of HIV therapies. HIV maturation inhibitors block virus r ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk

    SBC: ZENAGENE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy

    SBC: FOR-ROBIN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This proposal aims to develop a novel, highly-specific targeted therapy for treatment of breast cancer. The long-term objective is to convert the proprietary intellectual property, the mouse monoclonal antibody (McAb)JAA-F11, which targets the pancarcinoma Thomsen-Friedenreich antigen (TF-Ag) to a humanized form for use as an adjunct with conventional therapy ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Mobile App Targeting Meth Use, HIV Sex Risks and ART Adherence for Gay/Bisexual Men

    SBC: COG ANALYTICS, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Methamphetamine use among gay and bisexually identified men (GBM) and other men who have sex with men (MSM) is strongly associated with HIV infection due to the concomitant high-risk sexual behaviors that often occur while using the drug. As a result, HIV prevalence is significantly higher among MSM that report frequent use of methamphetamine and highest among ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Live-Cell Fluorescence Lifetime FRET Assays for HTS

    SBC: Fluorescence Innovations, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government